Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?

Vincenzo Emanuele Chiuri, Vito Lorusso

Research output: Contribution to journalArticle


Estrogen receptor expression in breast cancer cells represents an important predictive and prognostic factor. The estrogen receptor is a target for endocrine therapy, which avoids chemotherapy especially in highly hormone-sensitive early breast cancer. Paradoxically, recent data from several clinical trials and meta-analyses have demonstrated the superiority of adjuvant chemotherapy independently of age, estrogen receptor and nodal status. For this reason, new tools are needed to better define the intrinsic characteristics of breast cancers and to establish the role of cytotoxic treatment for those tumors with potentially good outcome, such as hormone-sensitive early breast cancer.

Original languageEnglish
Pages (from-to)18-22
Number of pages5
Issue numberSUPPL. 1
Publication statusPublished - Feb 2010



  • Chemotherapy
  • Early breast cancer
  • Estrogen receptor
  • HER2
  • Hormone therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this